Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Efficacy and Safety of TD-1473 in Crohn's Disease

ClinicalTrials.gov ID: NCT03635112

Public ClinicalTrials.gov record NCT03635112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy With 2 Doses of TD-1473 in Subjects With Moderately-to-Severely Active Crohn's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.

Study identification

NCT ID
NCT03635112
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Theravance Biopharma
Industry
Enrollment
167 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 18, 2018
Primary completion
Dec 29, 2021
Completion
Dec 29, 2021
Last update posted
Mar 12, 2023

2018 – 2021

United States locations

U.S. sites
44
U.S. states
19
U.S. cities
42
Facility City State ZIP Site status
Theravance Biopharma Investigational Site Birmingham Alabama 35233-2110
Theravance Biopharma Investigational Site Mobile Alabama 36688
Theravance Biopharma Investigational Site Scottsdale Arizona 85259-5499
Theravance Biopharma Investigational Site La Jolla California 92093
Theravance Biopharma Investigational Site Los Angeles California 90048
Theravance Biopharma Investigational Site Oakland California 94612
Theravance Biopharma Investigational Site Santa Monica California 90404
Theravance Biopharma Investigational Site Aventura Florida 33180
Theravance Biopharma Investigational Site Clearwater Florida 33765
Theravance Biopharma Investigational Site Hialeah Florida 33013
Theravance Biopharma Investigational Site Hollywood Florida 33021
Theravance Biopharma Investigational Site Largo Florida 33777
Theravance Biopharma Investigational Site Miami Florida 33135
Theravance Biopharma Investigational Site New Port Richey Florida 34653
Theravance Biopharma Investigational Site St. Petersburg Florida 33710
Theravance Biopharma Investigational Site Tampa Florida 33603
Theravance Biopharma Investigational Site Tampa Florida 33606
Theravance Biopharma Investigational Site New Lenox Illinois 60451
Theravance Biopharma Investigational Site Kansas City Kansas 66160
Theravance Biopharma Investigational Site Louisville Kentucky 40202
Theravance Biopharma Investigational Site Rockville Maryland 20850
Theravance Biopharma Investigational Site Brockton Massachusetts 02302
Theravance Biopharma Investigational Site Wyoming Michigan 49519
Theravance Biopharma Investigational Site St Louis Missouri 63110
Theravance Biopharma Investigational Site Las Vegas Nevada 89133
Theravance Biopharma Investigational Site Utica New York 13502
Theravance Biopharma Investigational Site Gastonia North Carolina 28504
Theravance Biopharma Investigational Site Greenville North Carolina 27834
PMG Research of Salisbury Salisbury North Carolina 28144
Theravance Biopharma Investigational Site Tulsa Oklahoma 74136
Theravance Biopharma Investigational Site Pittsburgh Pennsylvania 15212
Theravance Biopharma Investigational Site Uniontown Pennsylvania 15401
Theravance Biopharma Investigational Site Orangeburg South Carolina 29118
Theravance Biopharma Investigational Site Rock Hill South Carolina 29732
Theravance Biopharma Investigational Site Boerne Texas 78006
Theravance Biopharma Investigational Site El Paso Texas 79936
Theravance Biopharma Investigational Site Garland Texas 75044
Theravance Biopharma Investigational Site Harlingen Texas 78550
Theravance Biopharma Investigational Site Houston Texas 77058
Theravance Biopharma Investigational Site San Antonio Texas 78215
Theravance Biopharma Investigational Site San Antonio Texas 78229
Theravance Biopharma Investigational Site Southlake Texas 76092
Theravance Biopharma Investigational Site Spring Texas 77386
Theravance Biopharma Investigational Site Lansdowne Town Center Virginia 20176

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 134 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03635112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 12, 2023 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03635112 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →